Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...
FDA Approves Trastuzumab Biosimilar Trastuzumab-strf
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
Immunotherapy Outcomes in Patients With Primary Cardiac Soft-Tissue Sarcomas
In a U.S. multicenter retrospective analysis reported in JACC: CardioOncology, Amin H. Nassar, MD, and colleagues found that immune checkpoint inhibition resulted in mostly moderate activity in patients with primary cardiac soft-tissue sarcomas. Study Details The study included 24 patients with ...
INDIGO Trial: IDH Inhibitor Improves Progression-Free Survival in Grade 2 IDH1/2-Mutated Gliomas
The oral IDH1/2 inhibitor vorasidenib significantly improved progression-free survival in patients with grade 2 gliomas expressing IDH1/2 mutations in the phase III INDIGO trial. These results, which were reported by lead author Ingo K. Mellinghoff, MD, FACP, of Memorial Sloan Kettering Cancer...
Polatuzumab Vedotin-piiq for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, 2023, polatuzumab vedotin-piiq was approved for use with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with diffuse large B-cell lymphoma (DLBCL)–not otherwise specified or those with high-grade B-cell lymphoma who have an International...
Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence
A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium...
Rwanda’s Vision for Increasing Cervical Cancer Prevention One Village at a Time
Cervical cancer is a serious problem in many low- and middle-income countries such as the African country of Rwanda. Although the cervical cancer rate in Rwanda remains more than twice the U.S. rate, there has been improvement in recent years that cancer research organizations can learn from to...
Patients With Multiple Myeloma May Experience Poorer Outcomes in the Real World Compared With Reported Outcomes From Clinical Trials
Researchers identified a 75% higher rate of mortality among patients treated for multiple myeloma in real-world hospital settings compared with rates reported in clinical trials involving common therapies. The new findings were presented by Visram et al at the 2023 American Society of Hematology...
